• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

ARIAD Pharmaceuticals Inc - Articles and news items

ariad

Incyte to acquire ARIAD’s European operations for $140m

Industry news / 9 May 2016 / Victoria White, Digital Content Producer

The companies will also enter into a license agreement whereby Incyte will obtain an exclusive license to develop and commercialise Iclusig…

Atezolizumab

Ariad presents updated clinical data on brigatinib in patients with ALK+ NSCLC

Industry news / 21 April 2015 / Victoria White

ARIAD has announced updated clinical data on its tyrosine kinase inhibitor, brigatinib, in patients with ALK+ NSCLC from an ongoing Phase 1/2 trial…

ARIAD

Ariad announces preliminary safety and efficacy data of ponatinib in patients with newly diagnosed cml from discontinued Phase 3 epic trial

Industry news / 4 June 2014 / ARIAD Pharmaceuticals Inc

ARIAD Pharmaceuticals, Inc. announced preliminary safety and efficacy data from the discontinued Phase 3 EPIC trial of Iclusig® (ponatinib) vs. imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia…

ARIAD

ARIAD announces that Iclusig(TM) receives positive CHMP opinion for approval in the European Union

Industry news, News / 22 March 2013 / Biosector 2

Positive opinion on the marketing authorization application for Iclusig™…

Jonathan E. Dickinson, General Manager, ARIAD Pharmaceuticals (Europe), Sàrl.

ARIAD announces appointment of European General Manager and other key members of leadership team

Industry news, News / 21 February 2013 / Biosector 2

ARIAD announced the appointment of Jonathan E. Dickinson…

Merck logo

Update on FDA Advisory Committee vote on investigational medicine Ridaforolimus

Industry news, News / 20 March 2012 / Merck

“Merck remains confident in the potential of the investigational agent ridaforolimus…”

Merck logo

FDA accepts New Drug Application filing for ridaforolimus, investigational mTOR inhibitor

Industry news, News / 5 October 2011 / Merck

The FDA accepted for filing and review the New Drug Application for ridaforolimus…

Merck logo

EMA accepts marketing authorization application for Ridaforolimus, investigational mTOR inhibitor

Industry news, News / 18 August 2011 /

Merck to pay ARIAD $25 million milestone payment for acceptance of filing…

Merck logo

Merck and ARIAD announce presentation of results of Phase III SUCCEED trial

Industry news, News / 6 June 2011 / Merck

Merck and ARIAD Pharmaceuticals, Inc., announced the presentation of detailed results from the Phase III SUCCEED clinical trial…

 

Win an Amazon Gift Card worth up to €100!TAKE OUR SURVEY
+ +